IL17F and colorectal carcinoma: In contrast with TNF‐α and IL‐6, IL‐17A, IL‐17F, and IL‐22 exhibit antitumor effects by enhancing immune cell recruitment and tissue repair and by inhibiting inflammation and proangiogenic factors in CRC [64].